ArticleInternational journal of pharmaceutics: X2026
Multifunctional armored nanoemulsion of elemene combining ferroptosis induction and gut homeostasis restoration in colorectal cancer therapy.
Article in International journal of pharmaceutics: X, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer remains a leading cause of death worldwide. Colorectal cancer (CRC) is the most common type of gastrointestinal malignancy, with the combined effect of multiple etiological factors. Multifunctional nanocomposites present a promising platform for synergistic therapy of CRC. Elemene (EL), an active component in traditional Chinese medicine, exhibits both antitumor and immunostimulatory activities. However, its clinical application is limited by poor stability, low tumor accumulation, and the difficulty of effectively harnessing its dual activities. Herein, we developed an orally administered, colon-targeted nanoemulsion, LMP@EL-CNE, comprising EL cationic nanoemulsions (EL-CNE) armored with a low-methoxyl pectin (LMP) polysaccharide shell. This system exhibits dual responsiveness to colonic microflora enzymes and pH, allowing for prolonged retention and targeted drug release in the colon. Subsequently, it generates ultra-small EL nanodroplets (∼20 nm), which enhance tumor penetration and accumulation. Notably, LMP@EL-CNE induces mitochondrial dysfunction and downregulates glutathione peroxidase 4 (GPX4), a key regulator of ferroptosis. This disruption of the balance unlocks a more potent ferroptosis response, amplifying EL's intrinsic activity in CT26 cells. In an Chemical compounds studied in this article: Elemene (EL CAS No. 33880-83-0) the primary active pharmaceutical ingredient (API) with antitumor activity Polyoxyethylene hydrogenated castor oil (RH40, CAS No. 61788-85-0), a key non-ionic surfactant for nanoemulsion stabilization.Hexadecyl trimethyl ammonium bromide (CTAB, CAS No. 57-09-0), a cationic surfactant used in the nanoemulsion formulation.Low-methoxyl pectin (LMP, CAS No. 9000-69-5), an anionic polysaccharide constituting the functional "armor" of the nanoemulsion.Liproxstatin-1 (Lip-1, CAS No. 950455-15-9), a potent ferroptosis inhibitor used for mechanistic validation.Glutathione (GSH, reduced form, CAS No. 70-18-8), a central antioxidant, quantified to assess the status of the GPX4-mediated ferroptosis defense system.Malondialdehyde (MDA, CAS No. 542-78-9), the primary end-product of lipid peroxidation, quantified as a key indicator of ferroptosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.